@Puru chan:$AbbVie(ABBV)$AbbVie Inc. will present 23 abstracts at the 31st European Academy of Dermatology and Venerology (EADV) Congress in Milan, virtually and in-person, in September 2022. Data presented at the congress will provide dermatologic clinicians with studies and results regarding immune-mediated skin diseases such as psoriatic arthritis, psoriasis, atopic dermatitis, and vitiligo.1Some of the most notable discussions will include data on:The ongoing phase 3 active psoriatic arthritis clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the long-term efficacy and safety of risankizumab (SKYRIZI; Abbvie) for the treatment of psoriatic arthritisAnalyses from MEASURE-AD, a cross-sectional burden of disease study designed to identify global treatm